When is the next results date for IOL Chemicals?

No Upcoming Board Meetings

What does IOL Chemicals do?

IOL Chemicals and Pharmaceuticals Ltd specializes in Active Pharmaceutical Ingredients (APIs) and specialty chemicals, with a market cap of Rs 2,609 Cr and reported net sales of 528 Cr and net profit of 31 Cr for Q1 2025. The company, established in 1986, operates in the Pharmaceuticals & Biotechnology industry.

Overview:<BR>IOL Chemicals and Pharmaceuticals Ltd is a prominent player in the Active Pharmaceutical Ingredient (API) and specialty chemicals sectors, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap company.<BR><BR>History:<BR>Incorporated in September 1986, IOL Chemicals has established itself in the pharmaceutical sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 528 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 31 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 2,609 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 25.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.91%<BR>- Debt Equity: -0.06<BR>- Return on Equity: 5.99%<BR>- Price to Book: 1.51<BR><BR>Contact Details:<BR>Address: Trident Complex, Raikot Road Barnala Sangrur Punjab : 148101<BR>Tel: 91-01679-244701-07<BR>Email: contact@iolcp.com<BR>Website: http://www.iolcp.com

Who are in the management team of IOL Chemicals?

As of March 2023, the management team of IOL Chemicals includes Varinder Gupta (Managing Director), Vikas Gupta (Joint Managing Director), Kushal Kumar Rana (Director), Abhiraj Gupta (Executive Director), and Abhay Raj Singh (Company Secretary). The board also features independent directors such as Rajender Mohan Malla (Chairman), Sandhya Mehta, Harpal Singh, and Sharad Tyagi.

As of March 2023, the management team of IOL Chemicals includes the following individuals:<BR><BR>1. Varinder Gupta - Managing Director<BR>2. Vikas Gupta - Joint Managing Director<BR>3. Kushal Kumar Rana - Director (Works)<BR>4. Abhiraj Gupta - Executive Director<BR>5. Abhay Raj Singh - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent and non-executive directors, including:<BR>- Sandhya Mehta - Non-Executive & Independent Director<BR>- Rajender Mohan Malla - Chairman & Independent Director<BR>- Harpal Singh - Non-Executive & Independent Director<BR>- Sharad Tyagi - Independent Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

Has IOL Chemicals declared dividend?

IOL Chemicals & Pharmaceuticals Ltd has declared a 40% dividend, amounting to ₹4 per share, with an ex-date of February 18, 2025. The dividend yield is 0.91%, and total returns have varied across periods, with a notable 51.9% total return over the last 3 years.

IOL Chemicals & Pharmaceuticals Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: 4 per share<BR>- Ex-date: 18 Feb 25<BR><BR>Dividend Yield: 0.91%<BR><BR>Total Returns by Period:<BR>In the 6-month period, IOL Chemicals experienced a price return of 14.07%, a dividend return of 5.21%, leading to a total return of 19.28%.<BR><BR>For the 1-year period, the company had a price return of 22.11%, a dividend return of 5.28%, resulting in a total return of 27.39%.<BR><BR>Over the 2-year period, the price return was -0.4%, with a dividend return of 10.14%, culminating in a total return of 9.74%.<BR><BR>In the 3-year period, IOL Chemicals saw a price return of 31.67%, a dividend return of 20.23%, which contributed to a total return of 51.9%.<BR><BR>During the 4-year period, the company faced a price return of -36.5%, a dividend return of 15.37%, leading to a total return of -21.13%.<BR><BR>For the 5-year period, IOL Chemicals achieved a price return of 15.96%, a dividend return of 23.42%, resulting in a total return of 39.38%.<BR><BR>Overall, IOL Chemicals has declared a significant dividend and demonstrated varying total returns across different periods, with notable performance in the 3-year period. The dividend yield indicates a steady income for shareholders, complementing the price returns.

Who are the peers of the IOL Chemicals?

IOL Chemicals' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Novartis India, Indoco Remedies, Senores Pharma, SMS Pharma, and Syncom Formul. While IOL Chemicals has average management risk and a 1-year return of 23.27%, its growth is below average compared to its peers.

Peers: The peers of IOL Chemicals are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Novartis India, Indoco Remedies, Senores Pharma., SMS Pharma, and Syncom Formul.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, and the rest. Average management risk is found at IOL Chemicals, Novartis India, Indoco Remedies, SMS Pharma, and the rest. Below Average management risk is noted for Senores Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest, while IOL Chemicals, Divi's Lab., Indoco Remedies, Torrent Pharma, SMS Pharma, and the rest show below average growth. Good growth is seen at Novartis India, and Senores Pharma. has excellent growth. Capital structure is excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, IOL Chemicals, Novartis India, and the rest, while average capital structure is found at Indoco Remedies and SMS Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Novartis India has the lowest at -3.58%. IOL Chemicals has a 1-year return of 23.27%, which is higher than Novartis India but lower than Divi's Lab. Additionally, Indoco Remedies and SMS Pharma have negative six-month returns.

Is IOL Chemicals overvalued or undervalued?

As of May 19, 2025, IOL Chemicals is considered very expensive and overvalued compared to its peers, with key financial ratios significantly higher and lower returns, making it an unfavorable investment despite a recent strong performance.

As of 19 May 2025, the valuation grade for IOL Chemicals has moved from fair to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 25.73, an EV to EBITDA of 12.39, and a Price to Book Value of 1.54, which are significantly higher than many of its peers.<BR><BR>In comparison, Solar Industries has a PE ratio of 123.77 and an EV to EBITDA of 76.22, while Godrej Industries, which is rated attractive, has a PE ratio of 46.63 and an EV to EBITDA of 34.36. These comparisons highlight that IOL Chemicals is not only overvalued relative to its peers but also lacks competitive returns, with a ROE of 5.99% and a ROCE of 8.18%. Despite a strong 1-month return of 42.94% compared to the Sensex's 3.88%, the overall valuation indicates that IOL Chemicals is not a favorable investment at this time.

Who are the top shareholders of the IOL Chemicals?

The top shareholders of IOL Chemicals include Maya Devi Polycot Limited with 21.54%, Vasudeva Commercials Limited at 7.94%, and individual investors holding 31.43%. Mutual funds hold 0.02%, while Foreign Institutional Investors (FIIs) account for 1.47%.

The top shareholders of IOL Chemicals include the promoters, who hold a significant majority. The promoter with the highest holding is Maya Devi Polycot Limited, which owns 21.54% of the shares. Additionally, the highest public shareholder is Vasudeva Commercials Limited, holding 7.94%. Individual investors collectively hold 31.43% of the shares, while mutual funds have a minor stake through six schemes, accounting for 0.02%. Foreign Institutional Investors (FIIs) hold 1.47% of the company through 47 different entities.

How big is IOL Chemicals?

As of 24th July, IOL Chemicals & Pharmaceuticals Ltd has a market capitalization of 2,894.00 Cr, with recent net sales of 2,079.21 Cr and a net profit of 101.07 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: IOL Chemicals & Pharmaceuticals Ltd has a market capitalization of 2,894.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,079.21 Cr, while the sum of Net Profit for the same period is 101.07 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds are valued at 1,611.51 Cr, and Total Assets amount to 2,244.40 Cr.

Is IOL Chemicals technically bullish or bearish?

As of October 9, 2025, IOL Chemicals exhibits a mildly bullish trend supported by MACD and Bollinger Bands, though tempered by a mildly bearish KST and Dow Theory signals on the weekly chart.

As of 9 October 2025, the technical trend for IOL Chemicals has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by weekly and monthly MACD indicators both showing bullish signals. The Bollinger Bands also reflect a mildly bullish trend in both time frames. However, the KST indicates a mildly bearish stance on the weekly chart, and Dow Theory shows a mildly bearish trend on the weekly level with no trend on the monthly. The daily moving averages are mildly bullish, but the overall strength is tempered by the recent price action, including a decline from the previous close.

Are IOL Chemicals latest results good or bad?

IOL Chemicals' latest results show strong year-on-year growth, with a 56.50% increase in net profit and record revenue of ₹567.53 crores. However, there are concerns due to an 11.67% decline in net profit from the previous quarter and contracting operating margins, indicating potential challenges ahead.

IOL Chemicals' latest results present a mixed picture. On one hand, the company achieved a significant year-on-year increase in net profit, which surged by 56.50% to ₹29.97 crores compared to the same quarter last year. Additionally, revenue reached an all-time high of ₹567.53 crores, reflecting a 7.95% increase year-on-year and a 2.87% growth quarter-on-quarter.<BR><BR>However, the sequential performance raises concerns. The net profit declined by 11.67% from the previous quarter, which indicates potential challenges in maintaining profitability. Operating margins also contracted, falling from 11.26% in the previous quarter to 10.06%, suggesting pressure on margins despite the revenue growth.<BR><BR>Overall, while the year-on-year results are strong and indicate operational improvements, the sequential decline in profit and margins points to underlying issues that could affect sustainability. Investors should keep an eye on these trends to assess the company's future performance.

How has been the historical performance of IOL Chemicals?

IOL Chemicals has experienced a declining trend in net sales and profits over the past few years, with net sales dropping from 2,217.11 Cr in March 2023 to 2,079.21 Cr in March 2025, and profit after tax decreasing from 134.43 Cr to 101.07 Cr in the same period. Despite this, total assets increased to 2,382.07 Cr in March 2025.

Answer:<BR>The historical performance of IOL Chemicals shows a declining trend in net sales and profits over the past few years.<BR><BR>Breakdown:<BR>IOL Chemicals reported net sales of 2,079.21 Cr in March 2025, down from 2,132.79 Cr in March 2024 and 2,217.11 Cr in March 2023, indicating a consistent decrease in revenue. Total operating income mirrored this decline, with figures of 2,079.21 Cr in March 2025 compared to 2,132.79 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 1,876.91 Cr in March 2025 from 1,902.20 Cr in March 2024. Operating profit (PBDIT) fell to 224.71 Cr in March 2025, down from 260.66 Cr in March 2024, while profit before tax decreased to 137.96 Cr from 181.65 Cr. Consequently, profit after tax was 101.07 Cr in March 2025, a decline from 134.43 Cr in March 2024. The company's total assets increased to 2,382.07 Cr in March 2025 from 2,244.40 Cr in March 2024, while total liabilities also rose to 2,382.07 Cr from 2,244.40 Cr. Cash flow from operating activities was 178.00 Cr in March 2025, down from 289.00 Cr in March 2024, but net cash inflow improved to 70.00 Cr from 6.00 Cr. Overall, the financial metrics reflect a challenging period for IOL Chemicals, characterized by declining sales and profits despite an increase in total assets.

Should I buy, sell or hold IOL Chemicals?

Which are the latest news on IOL Chemicals?

Why is IOL Chemicals falling/rising?

As of 04-Dec, IOL Chemicals & Pharmaceuticals Ltd's stock price is at 86.74, down 0.18% and has declined 5.37% over the last six days, underperforming the Sensex. While it has gained 6.72% year-to-date, it lags behind the Sensex's 9.12%, and despite a significant five-year decline of 44.48%, increased delivery volume and a low debt-to-equity ratio suggest some investor interest and financial stability.

As of 04-Dec, IOL Chemicals & Pharmaceuticals Ltd's stock price is currently at 86.74, reflecting a decrease of 0.16, or 0.18%. The stock has been on a downward trend, having fallen for the last six consecutive days, resulting in a total decline of 5.37% during this period. This performance is notably worse than the benchmark Sensex, which has only decreased by 0.53% over the same week.<BR><BR>In terms of longer-term performance, the stock has seen a decline of 6.60% over the past month, contrasting with a positive return of 2.16% for the Sensex. Year-to-date, IOL Chemicals has a gain of 6.72%, but this is still below the Sensex's return of 9.12%. Over the past year, the stock has outperformed the Sensex with an increase of 11.22% compared to the Sensex's 5.32%. However, the five-year performance shows a significant decline of 44.48%, while the Sensex has increased by 89.14%.<BR><BR>Despite the recent price drop, there are some positive indicators. The stock's delivery volume has increased by 44.8% compared to its five-day average, suggesting rising investor participation. Additionally, the company's low debt-to-equity ratio indicates financial stability, which is a positive factor for investors.<BR><BR>Overall, the stock's current decline can be attributed to its recent performance trends and the broader market context, despite some positive signs in investor activity and financial health.